Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label extension study of SHR-1918 in homozygous familial hypercholesterolemia
CTR20253284Phase 2Active
- Sponsor
- Beijing Shengdi Pharmaceutical
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1918 in homozygous familial hypercholesterolemia (HoFH), sponsored by Beijing Shengdi Pharmaceutical. Started Aug 2025; status: active.
02
Drugs
SHR-1918
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on CTR20253284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253284.